Eikonoklastes Therapeutics Competitors and Similar CompaniesClear all
Eikonoklastes Therapeutics's competitors and similar companies include BlueSky Immunotherapies, Avalia Immunotherapies, Seagen and Legend Biotech.
 Eikonoklastes Therapeutics Eikonoklastes Therapeutics is a developer of tissue factor (TF) immunotherapies for triple-negative breast cancer (TNBC) and several other diseases. |  BlueSky Immunotherapies BlueSky Immunotherapies (also known as BlueSky Vaccines) is a company focusing on developing next-generation immunotherapies against infectious diseases and cancer. |  Avalia Immunotherapies Avalia Immunotherapies is a company that develops immune system modulators and vaccines for the treatment and prevention of infectious diseases and cancer. |  Seagen Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer. |  Legend Biotech Legend Biotech is a biopharmaceutical company engaged in the discovery and development of cell therapies for oncology and other indications.
| |
Founding Date | Founding Date 2019 | Founding Date 2017 | Founding Date 2015 | Founding Date 1998 | Founding Date 2014 |
Type | Type Private | Type Private | Type Private | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Cincinnati, US HQ | Locations Wien, AT HQ | Locations Lower Hutt, NZ HQ | Locations Bothell, US HQ Mississauga, CA Hørsholm, DK Rueil Malmaison, FR München, DE Milano, IT Schiphol, NL see more | Locations Somerset, US HQ Ghent, BE Nanjing, CN Hong Kong, HK Dublin, IE Piscataway, US |
Employees | Employees 8 | Employees 8 | Employees 4 | Employees 3,25622% increase | Employees 2,90012% increase |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $2b (FY, 2022) | Revenue (est.) $1b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $410.1m (FY, 2022) | Cost of goods $408.1m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $1.6b (FY, 2022) | Gross profit $620.8m (FY, 2025) |
Net income | Net income N/A | Net income N/A | Net income N/A | Net income ($610.3m) (FY, 2022) | Net income ($296.8m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 1.1m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 164m | Total funding raised $ 150.5m |
For sources of this data, please see the company profile
View Company Profiles
BlueSky Immunotherapies
HQ
Wien, AT
Employees
8
BlueSky Immunotherapies (also known as BlueSky Vaccines) is a company focusing on developing next-generation immunotherapies against infectious diseases and cancer.
View companyAvalia Immunotherapies
HQ
Lower Hutt, NZ
Employees
4
Avalia Immunotherapies is a company that develops immune system modulators and vaccines for the treatment and prevention of infectious diseases and cancer.
View companySeagen
HQ
Bothell, US
Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer.
View companyLegend Biotech
HQ
Somerset, US
Employees
2,900↑ 12% increase
Legend Biotech is a biopharmaceutical company engaged in the discovery and development of cell therapies for oncology and other indications.
View company